Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting

Background  The U.S. Food and Drug Administration (FDA) Adverse Event (AE) Reporting System (FAERS) is a global passive surveillance repository requiring mandatory updates by pharmaceutical manufacturers. Oral antiplatelet agents (OAAs) including aspirin (acetylsalicylic acid [ASA]) are broadly used to prevent thrombosis, at the expense of extra bleeding risks. However, the OAA filing quality and their comparative patterns in FAERS are unknown. We assessed completeness of original annual FAERS reports for OAA with special attention on ASA. Methods  We extracted AE cases co-reported with OAA including ASA, clopidogrel, prasugrel, ticagrelor, vorapaxar, or their combination. The 2015 FAERS cases were examined based on OAA distribution, suspected causative role, missing gender or age, and most common AEs after ASA. Results  A total of 1,187,729 reports qualified the inclusion criteria. The majority ( n  = 1,121,989) of the reports contain no reference of OAA, while 65,730 reports contain reference of at least one OAA, including 47,900 ASA cases. Therapy with ASA was heavily (>50%) underreported when used with prasugrel or ticagrelor, but still dominant (72.8%) among OAAs, followed by clopidogrel (18.7%), prasugrel (4.1%), ticagrelor (3.6%), and anecdotal vorapaxar (0.05%). Despite current recommendations, some (0.73%) reports contain multi-OAAs. The primary role of ASA in AE reporting was seldom (<1%), followed by clopidogrel (2.9%), prasugrel (3.7%), and highest for ticagrelor (9.3%). Missing gender after OAA was not common (<10%), but age was missing in approximately 25% of reports. Bleeding was the most frequent AE associated with ASA. Conclusion  The quality of reporting for OAA in general and ASA in particular can be improved by stricter FDA rules, better surveillance, and enforcements. Heavy ASA underreporting during dual antiplatelet therapy and missed demographic variables challenge outcome research capacities for establishing drug interactions in FAERS.

[1]  V. Serebruany,et al.  Worldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug Administration , 2018, European heart journal. Cardiovascular pharmacotherapy.

[2]  J. Manson,et al.  Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. , 2016, JAMA internal medicine.

[3]  Ruwen Böhm,et al.  OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications , 2016, PloS one.

[4]  Marc Boyer,et al.  Use of data mining at the Food and Drug Administration , 2016, J. Am. Medical Informatics Assoc..

[5]  C. Patrono.  The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. , 2015, Journal of the American College of Cardiology.

[6]  S. Windecker,et al.  Antiplatelet therapy for secondary prevention of coronary artery disease , 2014, Heart.

[7]  D. Angiolillo.  The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes , 2012, Drugs.

[8]  D. Angiolillo,et al.  The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes , 2012, Drugs.

[9]  Gianni Tognoni,et al.  Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.

[10]  Garret A FitzGerald,et al.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.

[11]  Deepak L. Bhatt,et al.  Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. , 2005, The American journal of cardiology.

[12]  C. Hennekens,et al.  An update on aspirin in the primary prevention of cardiovascular disease. , 2003, Archives of internal medicine.

[13]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[14]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[15]  Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction. , 1998, Federal register.